[Federal Register: January 2, 2002 (Volume 67, Number 1)]
[Notices]
[Page 83]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02ja02-73]
[[Page 83]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Blood Products Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of Food and Drug Administration (FDA). At least one portion
of the meeting will be closed to the public.
Name of Committee: Blood Products Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on January 16, 2002, from
10 a.m. to 12:30 p.m.
Location: Holiday Inn, Versailles Ballrooms I and II, 8120
Wisconsin Ave., Bethesda, MD.
Contact: William Freas, or Sheila D. Langford, Center for Biologics
Evaluation and Research (CBER) (HFM-17), Food and Drug Administration,
1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area), code 19516. Please call the Information Line
for up-to-date information on this meeting.
Agenda: On January 16, 2002, the committee will hear presentations
relevant to the site visit report on the review of the research
programs of the Laboratory of Bacterial, Parasitic, and Unconventional
Agents, and the Laboratory of Molecular Virology, Division of Emerging
and Transfusion Transmitted Diseases, Office of Blood Research and
Review, CBER.
Procedure: On January 16, 2002, from 10:00 a.m. to 10:45 a.m., and
from 11:30 a.m. to 12:30 p.m. the meeting is open to the public.
Interested persons may present data, information, or views, orally or
in writing, on issues pending before the committee. Written submissions
may be made to the contact person by January 9, 2002. Oral
presentations from the public will be scheduled between approximately
11:30 a.m. to 12:30 p.m. on January 16, 2002. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before January 9, 2002,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Closed Committee Deliberations: On January 16, 2002, from 10:45
a.m. to 11:30 a.m., the meeting will be closed to permit discussion
where disclosure would constitute a clearly unwarranted invasion of
personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the
reports of the review of individual research programs in the Division
of Emerging and Transfusion Transmitted Diseases, Office of Blood
Research and Review, Center for Biologics Evaluation and Research.
FDA regrets that it was unable to publish this notice 15 days prior
to the January 16, 2002, Blood Products Advisory Committee meeting.
Because the agency believes there is some urgency to bring this issue
to public discussion and qualified members of the Blood Products
Advisory Committee were available at this time, the Commissioner of
Food and Drugs concluded that it was in the public interest to hold
this meeting even if there was not sufficient time for the customary
15-day public notice.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: December 26, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-32253 Filed 12-27-01; 5:02 pm]
BILLING CODE 4160-02-S